[Skip to the reading](#main) [South Carolina Peptides](/) Common South Carolina myths, tested calmly, charts included. Merchandise absent. [Access](/#access) [Medicine](/#medicine) [Evidence](/#evidence) [Costs](/#costs) [Questions](/#questions) [Access](/#access) [Medicine](/#medicine) [Evidence](/#evidence) [Costs](/#costs) [Questions](/#questions) [Different care paths](/briefing) [Questions for a visit](/question-brief) [Home](/) Medicine # Weight care depends on the drug and the person A familiar ingredient name does not name every form, approved use or compounded drug. Bring the exact planned medicine into the talk. [Read this briefing](#reading) Access [Different care paths](/briefing) [Where care happens](/access-briefing) [Prescriber records](/license-briefing) [Clinical roles](/nurse-briefing) [Remote assessment](/telehealth-briefing) [Care across state lines](/state-lines-briefing) Medicine [Pharmacy permits](/pharmacy-briefing) [Compounding conditions](/compounding-briefing) [The HHS draft policy](/draft-policy-briefing) [Weight care](/weight-care-briefing) Evidence [Reading evidence](/evidence-brief) [Discussing risks](/risk-brief) [Research labels](/research-briefing) Costs [The whole cost](/cost-brief) [Coverage decisions](/coverage-brief) Questions [Questions for a visit](/question-brief) [Reporting a concern](/complaint-briefing) Match the medicine to the record. ## The myth that a familiar name makes every version equivalent Ask the prescriber to write the full medicine name and the form being looked at. Ask what concern it is intended to address. Keep those answers together. An ingredient nickname is useful for finding a talk, but the care decision needs a more precise account. The same applies when a friend or an advertisement supplies the name that started the search. FDA is short for the Food and Drug Administration. [FDA application records](https://api.fda.gov/drug/drugsfda.json) , checked November 3, 2026, show approved products containing semaglutide (Wegovy, Ozempic). The same records show approved tirzepatide (Zepbound, Mounjaro) products and their exact uses. An approved product does not lend approval to a compounded drug carrying the same ingredient name. ## The form is part of the name By November 3, 2026, both Ozempic and Wegovy names covered semaglutide tablet and injection forms. [FDA’s tablet naming record](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/213051Orig1s030ltr.pdf) is one reason to avoid assuming that a familiar name always means an injection. Form and approved use belong in the same talk as the ingredient. Ask the person treating you to find the label for the product planned. The label gives the official details about that product, including its approved uses. There is no need to compare every available form on your own before the visit. The useful task is to make the care plan clear enough to talk about. ## A shortage has a precise meaning The November 3, 2026 record reports that neither tirzepatide nor semaglutide appears on FDA’s national shortage list. A local difficulty finding a medicine does not itself recreate that national status. [FDA’s compounding update](https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize) distinguishes these questions because shortage status affects exceptions to restrictions on compounded copies. If availability is the concern, ask what the prescriber means by shortage and which source supports the claim. Then ask how the planned care would proceed. Keep availability, price and drug status as separate questions so an answer to one does not silently become an answer to the others. ## Adding something does not settle the copy question FDA’s policy checked November 3, 2026 says a vitamin addition can leave compounded semaglutide within the copy rule. The [copy-policy account](https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize) includes how the drug is given, its ingredient and its strength. To use the named-patient exception, the prescriber must record why the change is important for that person. The legal term is significant difference. A change in a drug’s name does not answer that test. Ask what the planned change would do for the need named in the check. If the explanation returns only to price or convenience, ask again about the reason it matters for that person. This is a question to take into the visit, rather than a way to decide a drug’s legal status from a short account. ## Care includes a health check and follow-up The South Carolina medical board’s posted obesity policy calls for a proper health check, testing, talk and follow-up. It is a longstanding policy, not a new rule requiring the same tests for everyone; this was checked November 3, 2026. [The policy](https://www.llr.sc.gov/med/Policies/Obesity.aspx) does not choose a medicine for the reader. Ask what will be assessed, when the plan gets a fresh review and which questions call for a later visit. Include cost and coverage before committing to ongoing care. A clear plan leaves room to look again at the approach when the person treating you has more details. ## Reading the source ### [FDA tablet naming record](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/213051Orig1s030ltr.pdf) Read the naming record that shows why a brand name alone does not specify a form. ### [FDA on compounded copies](https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize) Read national shortage and compounded-copy policy together. ### [State board obesity policy](https://www.llr.sc.gov/med/Policies/Obesity.aspx) Read the state board’s longstanding check and follow-up expectations. [ Continue with reading evidence ](/evidence-brief) South Carolina Peptides [Browse the briefings](/#all-briefings) [Visit questions](/question-brief) [Read the evidence](/evidence-brief) [Text edition](/weight-care-briefing.md) This guide tests South Carolina peptide myths against the record; it offers no treatment and sells nothing. © South Carolina Peptides